Clear All
11748 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69097-0578-74 69097-0578 nilotinib NILCEYA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0907-67 69097-0907 LANREOTIDE ACETATE LANREOTIDE ACETATE 60.0 mg/.2mL Hormonal Therapy Somatostatin Analog Subcutaneous May 30, 2025 In Use
72789-0473-30 72789-0473 PredniSONE PredniSONE Tablets, USP, 20 mg 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 30, 2025 In Use
69097-0578-91 69097-0578 nilotinib NILCEYA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
76282-0720-67 76282-0720 LANREOTIDE ACETATE LANREOTIDE ACETATE 120.0 mg/.5mL Hormonal Therapy Somatostatin Analog Subcutaneous May 30, 2025 In Use
76282-0719-67 76282-0719 LANREOTIDE ACETATE LANREOTIDE ACETATE 90.0 mg/.3mL Hormonal Therapy Somatostatin Analog Subcutaneous May 30, 2025 In Use
76282-0718-67 76282-0718 LANREOTIDE ACETATE LANREOTIDE ACETATE 60.0 mg/.2mL Hormonal Therapy Somatostatin Analog Subcutaneous May 30, 2025 In Use
69097-0577-91 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0577-74 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0578-56 69097-0578 nilotinib NILCEYA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0578-73 69097-0578 nilotinib NILCEYA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0576-08 69097-0576 nilotinib NILCEYA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0577-73 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0577-56 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0908-67 69097-0908 LANREOTIDE ACETATE LANREOTIDE ACETATE 90.0 mg/.3mL Hormonal Therapy Somatostatin Analog Subcutaneous May 30, 2025 In Use
71288-0186-20 71288-0186 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use
71288-0179-13 71288-0179 mitoXANTRONE mitoXANTRONE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous Jun 1, 2025 In Use
71288-0178-10 71288-0178 mitoXANTRONE mitoXANTRONE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous Jun 1, 2025 In Use
72205-0119-28 72205-0119 Sunitinib Malate Sunitinib Malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Jun 1, 2025 In Use
72205-0118-28 72205-0118 Sunitinib Malate Sunitinib Malate 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Jun 1, 2025 In Use
72205-0117-28 72205-0117 Sunitinib Malate Sunitinib Malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Jun 1, 2025 In Use
72205-0116-28 72205-0116 Sunitinib Malate Sunitinib Malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Jun 1, 2025 In Use
71288-0185-10 71288-0185 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use
71288-0184-05 71288-0184 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use
71288-0182-05 71288-0182 Daunorubicin hydrochloride Daunorubicin hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use

Found 11748 results — Export these results